Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chemotherapy, Adjuvant
/ mortality
Combined Modality Therapy
/ mortality
Female
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Japan
/ epidemiology
Lymphoma
/ mortality
Male
Middle Aged
Recurrence
Registries
Retrospective Studies
Rituximab
/ therapeutic use
Societies, Medical
Transplantation, Homologous
Treatment Outcome
Waldenstrom Macroglobulinemia
/ mortality
Allogeneic
Autologous
Stem cell transplantation
Waldenström’s macroglobulinemia
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
02
11
2019
accepted:
04
05
2020
pubmed:
20
5
2020
medline:
24
7
2020
entrez:
20
5
2020
Statut:
ppublish
Résumé
The role of stem cell transplantation (SCT) for patients with Waldenström's macroglobulinemia (WM) remains undetermined. Therefore, we retrospectively evaluated the outcome of autologous and allogeneic SCT for patients with WM using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-six patients receiving autologous and 31 receiving allogeneic SCT were analyzed. The allogeneic SCT group included more patients with advanced disease status at transplant and received more lines of chemotherapy. The cumulative incidences of non-relapse mortality (NRM) at 1 year were 30.0% (95% CI, 14.7-46.9%) in the allogeneic SCT and 0% in the autologous SCT group. The estimated 3-year overall (OS) and progression-free (PFS) survival rates were 84.5% (95% CI, 66.0-93.4%) and 70.8% (95% CI, 53.0-82.9%) in the autologous SCT group, and 52.2% (95% CI, 32.5-68.6%) and 45.0% (95% CI, 26.3-62.0%) in the allogeneic SCT group. No patients died after the first 2 years following allogeneic SCT. In univariate analyses, disease status at SCT was significantly associated with PFS in autologous SCT, and with OS and PFS in allogeneic SCT. These results suggest that both autologous and allogeneic SCT have each potential role in WM. Allogeneic SCT is more curative for WM, but is associated with high NRM.
Identifiants
pubmed: 32424672
doi: 10.1007/s00277-020-04078-3
pii: 10.1007/s00277-020-04078-3
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1635-1642Références
Owen RG, Treon SP, Al-Katib A et al (2003) Clinicopathological definition of Waldenström’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström’s Macroglobulinemia. Semin Oncol 30:110–115
doi: 10.1053/sonc.2003.50082
Iwanaga M, Chiang CJ, Soda M, Lai MS, Yang YW, Miyazaki Y, Matsuo K, Matsuda T, Sobue T (2014) Incidence of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003. Int J Cancer 134:174–180
doi: 10.1002/ijc.28343
Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D (2012) Waldenström macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma 53:1625–1626
doi: 10.3109/10428194.2012.656103
Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA (2016) Treatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia. Blood 128:1321–1328
doi: 10.1182/blood-2016-04-711234
Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB (2017) Diagnosis and management of Waldenström macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol 3:1257–1265
doi: 10.1001/jamaoncol.2016.5763
Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA, European Consortium for Waldenström's Macroglobulinemia (2018) Treatment and outcome patterns in European patients with Waldenström’s macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol 5:e299–e309
doi: 10.1016/S2352-3026(18)30087-5
Saito A, Isoda A, Kojima M, Yokohama A, Tsukune Y, Sasaki M, Ito S, Ohtsu A, Koike M, Murayama K, Moriya K, Tamura H, Matsumoto M, Nakahashi H, Tanosaki S, Sakura T, Kawamura T, Miyanaga T, Nakamura N, Murakami H, Handa H, Tsukamoto N (2017) Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan. Int J Hematol 106:681–690
doi: 10.1007/s12185-017-2297-y
Owen RG, Pratt G, Auer RL, Flatley R, Kyriakou C, Lunn MP, Matthey F, McCarthy H, McNicholl FP, Rassam SM, Wagner SD, Streetly M, D'Sa S, the British Committee for Standards in Haematology (2014) Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. Br J Haematol 165:316–333
doi: 10.1111/bjh.12760
Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N, Cazin B, Divine M, Dreyfus B, Cahn JY, Pignon B, Desablens B, Perrier JF, Bay JO, Travade P (2003) Transplantation in Waldenström’s macroglobulinemia--the French experience. Semin Oncol 30:291–296
doi: 10.1053/sonc.2003.50048
Anagnostopoulos A, Hari PN, Perez WS et al (2006) Autologous or allogeneic stem cell transplantation in patients with Waldenström’s macroglobulinemia. Biol Blood Marrow Transplant 12:845–854
doi: 10.1016/j.bbmt.2006.04.010
Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, Kolbe K, Gorin NC, Thomson K, Milpied N, Niederwieser D, Indrák K, Corradini P, Sureda A, Schmitz N (2010) High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28:2227–2232
doi: 10.1200/JCO.2009.24.4905
Kyriakou C, Canals C, Cornelissen JJ, Socié G, Willemze R, Ifrah N, Greinix HT, Blaise D, Deconinck E, Ferrant A, Schattenberg A, Harousseau JL, Sureda A, Schmitz N (2010) Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28:4926–4934
doi: 10.1200/JCO.2009.27.3607
Garnier A, Robin M, Larosa F, Golmard JL, le Gouill S, Coiteux V, Tabrizi R, Bulabois CE, Cacheux V, Kuentz M, Dreyfus B, Dreger P, Rio B, Moles-Moreau MP, Bilger K, Bay JO, Leblond V, Blaise D, Tournilhac O, Dhédin N (2010) Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica 95:950–955
doi: 10.3324/haematol.2009.017814
Usmani S, Sexton R, Crowley J, Barlogie B (2011) Autologous stem cell transplantation as a care option in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 11:139–142
doi: 10.3816/CLML.2011.n.032
Marzolini MA, Thomson KJ, Dorman J, D’Sa S (2014) BEAM-conditioned autologous SCT improves the quality of response in Waldenström’s macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre’s 10-year experience. Bone Marrow Transplant 49:1231–1232
doi: 10.1038/bmt.2014.113
Atsuta Y (2016) Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103:3–10
doi: 10.1007/s12185-015-1894-x
Swerdlow SH, Neal C (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4), Lyon
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15:367–369
doi: 10.1016/j.bbmt.2008.12.497
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458
doi: 10.1038/bmt.2012.244
Dreger P, Schmitz N (2007) Autologous stem cell transplantation as part of first-line treatment of Waldenström’s macroglobulinemia. Biol Blood Marrow Transplant 13:623–624
doi: 10.1016/j.bbmt.2007.01.083
Caravita T, Siniscalchi A, Tendas A, Cupelli L, Dentamaro T, Natale G, Spagnoli A, de Fabritiis P (2009) High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenström’s macroglobulinemia. Bone Marrow Transplant 43:587–588
doi: 10.1038/bmt.2008.360
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G (2009) International prognostic scoring system for Waldenström macroglobulinemia. Blood 113:4163–4170
doi: 10.1182/blood-2008-08-174961
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH (2015) Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 372:1430–1440
doi: 10.1056/NEJMoa1501548
Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, Kofides A, Patterson CJ, Meid K, Gustine J, Dubeau T, Palomba ML, Advani R, Castillo JJ, Furman RR, Hunter ZR, Treon SP (2017) Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood 129:2519–2525
doi: 10.1182/blood-2017-01-761726